Drug Candidate for Treatment of Pulmonary Arterial Hypertension
Ralinepag (APD811), is an oral, next-generation, selective IP receptor agonist targeting the prostacyclin pathway for the treatment of pulmonary arterial hypertension (PAH). Arena discovered and developed this investigational drug candidate internally. Ralinepag’s potency on vasodilation, inhibition of proliferation of vascular smooth muscle cells, and inhibition of platelet aggregation, combined with an extended half life support its application as a potentially best-in-class agent for the treatment of PAH.
About Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a rare, chronic, progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs. The increased pressure strains the heart, which can limit physical activity, result in heart failure and reduce life expectancy. Current treatment of PAH falls within four distinct therapeutic classes: endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, prostacyclin analogues and soluble guanylate cyclase (SGc) stimulators. The available therapies have positive effects in PAH, but they do not provide a cure, and in many patients the disease will progress.
We have initiated a randomized, double-blind and placebo-controlled Phase 2 clinical trial to evaluate the hemodynamic and exercise capacity effects, safety and tolerability of ralinepag.
Visit https://clinicaltrials.gov/ for more information.
|Drug Candidate||Disease Area||Target||Status||Retained Rights|
|Ralinepag (APD811)||Pulmonary Arterial Hypertension||IP Receptor Agonist||Phase 2 Trial Ongoing||Worldwide|
|Drug Candidate||Ralinepag (APD811)|
|Disease Area||Pulmonary Arterial Hypertension|
|Target||IP Receptor Agonist|
|Status||Phase 2 Trials Ongoing|
Ralinepag has not been approved by the US Food and Drug Administration or any other regulatory agency.